Journal of Clinical Investigation · 1997 · 917 citations · 44 references
MedicineCancer BiologyOncologyCell SignalingMolecular OncologySignal TransductionAngiogenesisAngiogenesis In CancerCorneal VascularizationEndothelial ActivationGrowth Factor SignalingAngiogenic ModulationEndothelial MigrationGuanylyl Cyclase RegulationNitric OxideNitric Oxide ProductionTumor Angiogenesis SignalingVascular Endothelial Growth FactorVascular Endothelial Growth Factor Signaling
Systemic administration of the nitric oxide (NO) synthase inhibitor Nomega-nitro--arginine methyl ester (L-NAME) to rabbits bearing a corneal implant blocked vascular endothelial growth factor (VEGF), but not basic fibroblast growth factor (bFGF)-induced angiogenesis. L-NAME completely blocked angiogenesis induced by VEGF-transfected MCF-7 breast carcinoma cells and the cells remained dormant in the cornea. Postcapillary endothelial cell migration and growth induced by VEGF were blocked by both the NO synthase inhibitor Nomega-mono-methyl--arginine and by the guanylate cyclase inhibitor LY 83583. We conclude that NO is a downstream imperative of VEGF-, but not bFGF-induced angiogenesis, and propose that the NO synthase/guanylate cyclase pathway is a potential target for controlling tumor angiogenesis in response to VEGF. Our studies support recent evidence that VEGF and bFGF induce angiogenesis by different mechanistic pathways using the alphavbeta5 and alphavbeta3 integrins, respectively.
44
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Dorit Shweiki, Ahuva Itin, Dov Soffer et al. · Nature · 1992 · 4.6K citations
K. Jin Kim, Bing Li, Jane Winer et al. · Nature · 1993 · 3.6K citations
Medicine, Cancer Biology, Oncology +14
Karl H. Plate, Georg Breier, Herbert A. Weich et al. · Nature · 1992 · 2.3K citations
Medicine, Cancer Biology, Oncology +16